1-3 of 3
Ulla Olsson-Strömberg, MD, PhD
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Increased Levels of Myeloid-Derived Suppressor Cells (MDSCs) in Chronic Myeloid Leukemia and the Effect of Tyrosine Kinase Inhibitors on MDSCs in Vitro

Lisa H Christiansson, M.Sc, Stina Söderlund, MD, Emma Svensson, Mats Bengtsson, MD, PhD, Bengt Simonsson, MD, PhD, Ulla Olsson-Strömberg, MD, PhD, Angelica Loskog, PhD
Journal: Blood
Blood (2011) 118 (21): 2744.
https://doi.org/10.1182/blood.V118.21.2744.2744
Published: 2011
Journal Articles

Favorable Therapeutic Responses in Newly Diagnosed CML-CP Patients Induced by Dasatinib Are Reflected At the CD34+CD38+ Progenitor Cell but Not At the CD34+CD38− Stem Cell Level: Results From Randomized NordCML006 Study

Satu Mustjoki, MD, PhD, Johan Richter, MD, PhD, Gisela Barbany, MD, PhD, Hans Ehrencrona, MD, PhD, Ingunn Dybedal, MD, PhD, Thoas Fioretos, MD, PhD, Tobias Gedde-Dahl, MD, PhD, Bjorn Gjertsen, MD, PhD, Randi Hovland, PhD, Sari E Jalkanen, MSc, Dag Josefsen, MD, PhD, Perttu Koskenvesa, MD, Carin Lassen, Msc, Kirsi Latvala, Waleed Majeed, MD, Claes Malm, MD, Berit Markevärn, MD, Ali Mosfegh, PhD, Lotta Ohm, MD, Tor Olofsson, MD, PhD, Ulla Olsson-Strömberg, MD, PhD, Katrin Rapakko, PhD, Kari Remes, MD PhD, Jesper Stentoft, MD, PhD, Leif Stenke, MD, PhD, Merja Suominen, MD, Sara Thunberg, PhD, Ole Weiss Bjerrum, MD, PhD, Bengt Simonsson, MD, PhD, Kimmo Porkka, MD, PhD, Henrik Hjorth-Hansen, MD, PhD
Journal: Blood
Blood (2011) 118 (21): 784.
https://doi.org/10.1182/blood.V118.21.784.784
Published: 2011
Journal Articles

The Proportion of Ph+ CD34 + CD38 neg Leukemic Stem Cells In the Bone Marrow of Newly Diagnosed Patients with Chronic Myeloid Leukemia (CML) In Chronic Phase (CP) Is Variable and Correlates with High Sokal Risk, High Leukocyte Count, Low Hemoglobin Concentration, Splenomegaly and Increased Hematological Toxicity During Initial TKI-Therapy. Data From a Randomized Phase II NordCML006 Study

Satu Mustjoki, MD, PhD, Johan Richter, MD, PhD, Gisela Barbany, MD, PhD, Ingunn Dybedal, MD, PhD, Thoas Fioretos, MD, PhD, Tobias Gedde-Dahl, MD, PhD, Bjorn T. Gjertsen, MD, PhD, Randi Hovland, PhD, Sari Jalkanen, Msc, Dag Josefsen, MD, PhD, Perttu Koskenvesa, MD, Carin Lassen, Kirsi Latvala, Waleed Majeed, MD, Claes Malm, MD, Berit Markevärn, MD, Ali Moshfegh, PhD, Lotta Ohm, MD, Tor Olofsson, MD, PhD, Ulla Olsson-Strömberg, MD, PhD, Katrin Rapakko, PhD, Kari Remes, MD, PhD, Jesper Stentoft, MD, PhD, Leif Stenke, MD, PhD, Merja Suominen, MD, Sara Thunberg, MD, PhD, Ole Weiss Bjerrum, MD, PhD, Bengt Simonsson, MD, PhD, Kimmo Porkka, MD, PhD, Henrik Hjorth-Hansen, MD, PhD
Journal: Blood
Blood (2010) 116 (21): 667.
https://doi.org/10.1182/blood.V116.21.667.667
Published: 2010